cagrisema phase 3 results 2025 cagrilintide semaglutide combination obesity
cagrisema phase 3 results 2025 cagrilintide semaglutide combination obesity HCPLive Another obesity contender just raised
Another obesity contender just raised the stakes. Novo Nordisk's CagriSema combination delivered around 20% mean weight loss in a large trial. The formula combines semaglutide with cagrilintide, giving the body multiple appetite control Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth Novo Nordisk's experimental obesity drug CagriSema shows blood pressure benefits Reuters The next frontier in metabolic health: Cagrilintide Semaglutide and the evolving landscape of therapies
USD25.88
USD45.88
Pay in 4 interest-free payments of $6.47 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
